Methicillin-Sensitive and Methicillin-Resistant Staphylococcus aureus: Preventing Surgical Site Infections Following Plastic Surgery

Aesthetic Surgery Journal

Volumn 29, Issue 3, 2009, Pages 232-244

  Elward, Alexis M ^a   McAndrews, Joanne M ^a   Young, V Leroy ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CEFAZOLIN; CEPHALOSPORIN DERIVATIVE; CEPHAMYCIN DERIVATIVE; CHLORHEXIDINE; CHLORHEXIDINE GLUCONATE; CLINDAMYCIN; DAPTOMYCIN; DOXYCYCLINE; LINEZOLID; METICILLIN; OXACILLIN; PENICILLIN BINDING PROTEIN 2A; PENICILLIN G; PSEUDOMONIC ACID; PYRIDOXINE; RIFAMPICIN; TIGECYCLINE; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; BACTERIUM CULTURE; BACTERIUM ISOLATION; BONE MARROW SUPPRESSION; CLINICAL TRIAL; COST OF ILLNESS; CREATINE KINASE BLOOD LEVEL; CYTOPENIA; DISEASE SURVEILLANCE; DRUG ELIMINATION; DRUG MECHANISM; DRUG PENETRATION; ERADICATION THERAPY; ESTHETIC SURGERY; GOOD CLINICAL PRACTICE; HEALTH CARE COST; HEALTH INSURANCE; HOSPITAL INFECTION; HUMAN; INFECTION PREVENTION; INFECTION RISK; LABORATORY TEST; MEDICOLEGAL ASPECT; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SENSITIVE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MYOPATHY; NAUSEA AND VOMITING; NONHUMAN; PLASTIC SURGERY; PNEUMONIA; POLYMERASE CHAIN REACTION; POSTOPERATIVE COMPLICATION; POSTOPERATIVE TOXIC SHOCK SYNDROME; PRIORITY JOURNAL; REVIEW; SCREENING TEST; SIDE EFFECT; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; SURGICAL INFECTION; SURGICAL TECHNIQUE; THROMBOCYTOPENIA;

ANTI-BACTERIAL AGENTS; CARRIER STATE; COSMETIC TECHNIQUES; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; PREOPERATIVE CARE; RISK FACTORS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; SURGICAL WOUND INFECTION;

EID: 67650074872     PISSN: 1090820X     EISSN: 1527330X     Source Type: Journal    
DOI: 10.1016/j.asj.2009.01.010     Document Type: Review

References (171)

1. Classics in infectious diseases. "On abscesses." Alexander Ogston (1844-1929). Rev Infect Dis 6 (1984) 122-128
2. Leonard F.C., and Markey B.K. Meticillin-resistant Staphylococcus aureus in animals: A review. Vet J 175 (2008) 27-36
3. Martins A., and de L Cunha M. Methicillin resistance in Staphylococcus aureus and coagulase-negative staphylococci: Epidemiological and molecular aspects. Microbiol Immunol 51 (2007) 787-795
4. Jevons M.P., Coe A.W., and Parker M.T. Methicillin resistance in staphylococci. Lancet 1 (1963) 904-907
5. Rice L.B. Antimicrobial resistance in gram-positive bacteria. Am J Infect Control 34 5 Suppl 1 (2006) S11-S19
6. Barrett F., McGehee Jr. R.F., and Finland M. Methicillin-resistant Staphylococcus aureus at Boston City Hospital. Bacteriologic and epidemiologic observations. N Engl J Med 279 (1968) 441-448
7. Terushkin V., and Brownell I. Management of methicillin-resistant Staphylococcus aureus (MRSA) skin infections and MRSA colonization. J Drugs Dermatol 7 (2008) 597-601
8. Berger-Bachi B., and Rohrer S. Factors influencing methicillin resistance in staphylococci. Arch Microbiol 178 (2002) 165-171
9. Fekety R. Vancomycin, teicoplanin, and the streptogranins: Quinupristin and dalfopristin. In: Mandell G., Bennett J., and Dolin R. (Eds). Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 5th ed. Vol 1 (2000), Churchill Livingstone, Philadelphia, PA 383
10. Hiramatsu K., Hanaki H., Ino T., Yabuta K., Oguri T., and Tenover F.C. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 40 (1997) 135-136
11. Smith T.L., Pearson M.L., Wilcox K.R., et al. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N Engl J Med 340 (1999) 493-501
12. Clinical and Laboratory Standards Institute. M100-S17, performance standards for antimicrobial susceptibility testing. Seventeenth informational supplement (2007), Clinical and Laboratory Standards Institute, Wayne, PA
13. Appelbaum P.C. MRSA-the tip of the iceberg. Clin Microbiol Infect 12 Suppl 2 (2006) 3-10
14. Chang S., Sievert D.M., Hageman J.C., et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 348 (2003) 1342-1347
15. Tenover F.C., Weigel L.M., Appelbaum P.C., et al. Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania. Antimicrob Agents Chemother 48 (2004) 275-280
16. Aksoy D.Y., and Unal S. New antimicrobial agents for the treatment of Gram-positive bacterial infections. Clin Microbiol Infect 14 (2008) 411-420
17. Arbeit R.D., Maki D., Tally F.P., Campanaro E., and Eisenstein B.I. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 38 (2004) 1673-1681
18. Silverman J.A., Mortin L.I., Vanpraagh A.D., Li T., and Alder J. Inhibition of daptomycin by pulmonary surfactant: In vitro modeling and clinical impact. J Infect Dis 191 (2005) 2149-2152
19. Echevarria K., Datta P., Cadena J., and Lewis II J.S. Severe myopathy and possible hepatotoxicity related to daptomycin. J Antimicrob Chemother 55 (2005) 599-600
20. Cubicin [package insert] (2008), Cubist Pharmaceuticals, Lexington, MA
21. Abraham G., Finkelberg D., and Spooner L.M. Daptomycin-induced acute renal and hepatic toxicity without rhabdomyolysis. Ann Pharmacother 42 (2008) 719-721
22. Hirschwerk D., Ginocchio C.C., Bythrow M., and Condon S. Diminished susceptibility to daptomycin accompanied by clinical failure in a patient with methicillin-resistant Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol 27 (2006) 315-317
23. Mangili A., Bica I., Snydman D.R., and Hamer D.H. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 40 (2005) 1058-1060
24. Skiest D.J. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J Clin Microbiol 44 (2006) 655-656
25. Wilcox M.H. Efficacy of linezolid versus comparator therapies in Gram-positive infections. J Antimicrob Chemother 51 Suppl 2 (2003) ii27-ii35
26. Li Z., Willke R.J., Pinto L.A., et al. Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: A randomized, multicenter trial. Pharmacotherapy 21 (2001) 263-274
27. Li J.Z., Willke R.J., Rittenhouse B.E., and Glick H.A. Approaches to analysis of length of hospital stay related to antibiotic therapy in a randomized clinical trial: Linezolid versus vancomycin for treatment of known or suspected methicillin-resistant Staphylococcus species infections. Pharmacotherapy 22 (2002) 45S-54S
28. Swaney S.M., Aoki H., Ganoza M.C., and Shinabarger D.L. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother 42 (1998) 3251-3255
29. Weigelt J., Itani K., Stevens D., Lau W., Dryden M., and Knirsch C. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 49 (2005) 2260-2266
30. Birmingham M.C., Rayner C.R., Meagher A.K., Flavin S.M., Batts D.H., and Schentag J.J. Linezolid for the treatment of multidrug-resistant, Gram-positive infections: Experience from a compassionate-use program. Clin Infect Dis 36 (2003) 159-168
31. Gerson S.L., Kaplan S.L., Bruss J.B., et al. Hematologic effects of linezolid: Summary of clinical experience. Antimicrob Agents Chemother 46 (2002) 2723-2726
32. Spellberg B., Yoo T., and Bayer A.S. Reversal of linezolid-associated cytopenias, but not peripheral neuropathy, by administration of vitamin B6. J Antimicrob Chemother 54 (2004) 832-835
33. Frippiat F., Bergiers C., Michel C., Dujardin J.P., and Derue G. Severe bilateral optic neuritis associated with prolonged linezolid therapy. J Antimicrob Chemother 53 (2004) 1114-1115
34. Ferry T., Ponceau B., Simon M., et al. Possibly linezolid-induced peripheral and central neurotoxicity: Report of four cases. Infection 33 (2005) 151-154
35. Legout L., Senneville E., Gomel J.J., Yazdanpanah Y., and Mouton Y. Linezolid-induced neuropathy. Clin Infect Dis 38 (2004) 767-768
36. Huang V., and Gortney J.S. Risk of serotonin syndrome with concomitant administration of linezolid and serotonin agonists. Pharmacotherapy 26 (2006) 1784-1793
37. Projan S.J. Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent. Pharmacotherapy 20 (2000) 219S-223S
38. Ellis-Grosse E.J., Babinchak T., Dartois N., Rose G., and Loh E. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: Results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 41 Suppl 5 (2005) S341-S353
39. Sacchidanand S., Penn R.L., Embil J.M., et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial. Int J Infect Dis 9 (2005) 251-261
40. Florescu I., Beuran M., Dimov R., et al. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: A phase 3, multicentre, double-blind, randomized study. J Antimicrob Chemother 62 Suppl 1 (2008) i17-i28
41. Stein G.E., and Craig W.A. Tigecycline: A critical analysis. Clin Infect Dis 43 (2006) 518-524
42. Muralidharan G., Fruncillo R.J., Micalizzi M., Raible D.G., and Troy S.M. Effects of age and sex on single-dose pharmacokinetics of tigecycline in healthy subjects. Antimicrob Agents Chemother 49 (2005) 1656-1659
43. Williams R.E. Healthy carriage of Staphylococcus aureus: Its prevalence and importance. Bacteriol Rev 27 (1963) 56-71
44. Buehlmann M., Frei R., Fenner L., Dangel M., Fluckiger U., and Widmer A.F. Highly effective regimen for decolonization of methicillin-resistant Staphylococcus aureus carriers. Infect Control Hosp Epidemiol 29 (2008) 510-516
45. Gorwitz R.J., Kruszon-Moran D., McAllister S.K., et al. Changes in the prevalence of nasal colonization with Staphylococcus aureus in the United States, 2001-2004. J Infect Dis 197 (2008) 1226-1234
46. Kluytmans J., van Belkum A., and Verbrugh H. Nasal carriage of Staphylococcus aureus: Epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev 10 (1997) 505-520
47. Armstrong-Esther C.A. Carriage patterns of Staphylococcus aureus in a healthy non-hospital population of adults and children. Ann Hum Biol 3 (1976) 221-227
48. Centers for Disease Control and Prevention. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus-Minnesota and North Dakota, 1997-1999. MMWR 48 (1999) 707-710
49. Lindenmayer J.M., Schoenfeld S., O'Grady R., and Carney J.K. Methicillin-resistant Staphylococcus aureus in a high school wrestling team and the surrounding community. Arch Intern Med 158 (1998) 895-899
50. Panton P., and Valentine F. Staphylococcal toxin. Lancet 1 (1932) 506-508
51. Sabol K.E., Echevarria K.L., and Lewis II J.S. Community-associated methicillin-resistant Staphylococcus aureus: New bug, old drugs. Ann Pharmacother 40 (2006) 1125-1133
52. Kazakova S.V., Hageman J.C., Matava M., et al. A clone of methicillin-resistant Staphylococcus aureus among professional football players. N Engl J Med 352 (2005) 468-475
53. Cohen P.R. Cutaneous community-acquired methicillin-resistant Staphylococcus aureus infection in participants of athletic activities. South Med J 98 (2005) 596-602
54. Zinderman C.E., Conner B., Malakooti M.A., LaMar J.E., Armstrong A., and Bohnker B.K. Community-acquired methicillin-resistant Staphylococcus aureus among military recruits. Emerg Infect Dis 10 (2004) 941-944
55. Centers for Disease Control and Preventions. Methicillin-resistant Staphylococcus aureus skin infections among tattoo recipients-Ohio, Kentucky, and Vermont, 2004-2005. MMWR 55 (2006) 677-679
56. Baillargeon J., Kelley M.F., Leach C.T., Baillargeon G., and Pollock B.H. Methicillin-resistant Staphylococcus aureus infection in the Texas prison system. Clin Infect Dis 38 (2004) e92-e95
57. Rankin S., Roberts S., O'Shea K., Maloney D., Lorenzo M., and Benson C.E. Panton valentine leukocidin (PVL) toxin positive MRSA strains isolated from companion animals. Vet Microbiol 108 (2005) 145-148
58. van Duijkeren E., Wolfhagen M.J., Heck M.E., and Wannet W.J. Transmission of a Panton-Valentine leucocidin-positive, methicillin-resistant Staphylococcus aureus strain between humans and a dog. J Clin Microbiol 43 (2005) 6209-6211
59. Loeffler A., Boag A.K., Sung J., et al. Prevalence of methicillin-resistant Staphylococcus aureus among staff and pets in a small animal referral hospital in the UK. J Antimicrob Chemother 56 (2005) 692-697
60. Klevens R.M., Morrison M.A., Nadle J., et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298 (2007) 1763-1771
61. Kim T., Oh P.I., and Simor A.E. The economic impact of methicillin-resistant Staphylococcus aureus in Canadian hospitals. Infect Control Hosp Epidemiol 22 (2001) 99-104
62. Klein E., Smith D.L., and Laxminarayan R. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005. Emerg Infect Dis 13 (2007) 1840-1846
63. Abramson M.A., and Sexton D.J. Nosocomial methicillin-resistant and methicillin-susceptible Staphylococcus aureus primary bacteremia: At what costs?. Infect Control Hosp Epidemiol 20 (1999) 408-411
64. Kopp B.J., Nix D.E., and Armstrong E.P. Clinical and economic analysis of methicillin-susceptible and -resistant Staphylococcus aureus infections. Ann Pharmacother 38 (2004) 1377-1382
65. Capitano B., Leshem O.A., Nightingale C.H., and Nicolau D.P. Cost effect of managing methicillin-resistant Staphylococcus aureus in a long-term care facility. J Am Geriatr Soc 51 (2003) 10-16
66. Engemann J.J., Carmeli Y., Cosgrove S.E., et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis 36 (2003) 592-598
67. Rubin R.J., Harrington C.A., Poon A., Dietrich K., Greene J.A., and Moiduddin A. The economic impact of Staphylococcus aureus infection in New York City hospitals. Emerg Infect Dis 5 (1999) 9-17
68. Centers for Disease Control and Prevention Web site. Community-associated MRSA information for clinicians. (Accessed 8/1/08, at http://www.cdc.gov/ncidod/dhqp/ar_mrsa_ca_clinicians.html#7)
69. David M.Z., Glikman D., Crawford S.E., et al. What is community-associated methicillin-resistant Staphylococcus aureus?. J Infect Dis 197 (2008) 1235-1243
70. Calfee D.P., Durbin L.J., Germanson T.P., Toney D.M., Smith E.B., and Farr B.M. Spread of methicillin-resistant Staphylococcus aureus (MRSA) among household contacts of individuals with nosocomially acquired MRSA. Infect Control Hosp Epidemiol 24 (2003) 422-426
71. O'Brien F.G., Pearman J.W., Gracey M., Riley T.V., and Grubb W.B. Community strain of methicillin-resistant Staphylococcus aureus involved in a hospital outbreak. J Clin Microbiol 37 (1999) 2858-2862
72. Saiman L., O'Keefe M., Graham III P.L., et al. Hospital transmission of community-acquired methicillin-resistant Staphylococcus aureus among postpartum women. Clin Infect Dis 37 (2003) 1313-1319
73. Pottumarthy S., Fritsche T.R., and Jones R.N. Evaluation of alternative disk diffusion methods for detecting mecA-mediated oxacillin resistance in an international collection of staphylococci: Validation report from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 51 (2005) 57-62
74. Nagaoka T., Horii T., Satoh T., et al. Use of a three-dimensional microarray system for detection of levofloxacin resistance and the mec A gene in Staphylococcus aureus. J Clin Microbiol 43 (2005) 5187-5194
75. Zhang K., McClure J.A., Elsayed S., Louie T., and Conly J.M. Novel multiplex PCR assay for characterization and concomitant subtyping of staphylococcal cassette chromosome mec types I to V in methicillin-resistant Staphylococcus aureus. J Clin Microbiol 43 (2005) 5026-5033
76. Greif R., Akca O., Horn E.P., Kurz A., and Sessler D.I. Supplemental perioperative oxygen to reduce the incidence of surgical-wound infection. Outcomes Research Group. N Engl J Med 342 (2000) 161-167
77. Belda F.J., Aguilera L., de la Asunción J.G., et al. Supplemental perioperative oxygen and the risk of surgical wound infection: A randomized controlled trial. JAMA 294 (2005) 2035-2042
78. Kurz A., Sessler D.I., and Lenhardt R. Perioperative normothermia to reduce the incidence of surgical-wound infection and shorten hospitalization. Study of Wound Infection and Temperature Group. N Engl J Med 334 (1996) 1209-1215
79. Kurz A. Thermal care in the perioperative period. Best Pract Res Clin Anaesthesiol 22 (2008) 39-62
80. Zerr K.J., Furnary A.P., Grunkemeier G.L., Bookin S., Kanhere V., and Starr A. Glucose control lowers the risk of wound infection in diabetics after open heart operations. Ann Thorac Surg 63 (1997) 356-361
81. Mishriki S.F., Law D.J., and Jeffery P.J. Factors affecting the incidence of postoperative wound infection. J Hosp Infect 16 (1990) 223-230
82. Tanner J., Woodings D., and Moncaster K. Preoperative hair removal to reduce surgical site infection. Cochrane Database Syst Rev 3 (2006) CD004122.
83. Mosely L.H., and Finseth F. Cigarette smoking: Impairment of digital blood flow and wound healing in the hand. Hand 9 (1977) 97-101
84. Fawcett A., Shembekar M., Church J.S., Vashisht R., Springall R.G., and Nott D.M. Smoking, hypertension, and colonic anastomotic healing: A combined clinical and histopathological study. Gut 38 (1996) 714-718
85. Chan L.K., Withey S., and Butler P.E. Smoking and wound healing problems in reduction mammaplasty: Is the introduction of urine nicotine testing justified?. Ann Plast Surg 56 (2006) 111-115
86. Manassa E.H., Hertl C.H., and Olbrisch R.R. Wound healing problems in smokers and nonsmokers after 132 abdominoplasties. Plast Reconstr Surg 111 (2003) 2082-2087
87. Goodwin S.J., McCarthy C.M., Pusic A.L., et al. Complications in smokers after postmastectomy tissue expander/implant breast reconstruction. Ann Plast Surg 55 (2005) 16-19
88. Padubidri A.N., Yetman R., Browne E., et al. Complications of postmastectomy breast reconstructions in smokers, ex-smokers, and nonsmokers. Plast Reconstr Surg 107 (2001) 342-349
89. Araco A., Gravante G., Sorge R., Araco F., Delogu D., and Cervelli V. Wound infections in aesthetic abdominoplasties: The role of smoking. Plast Reconstr Surg 121 (2008) 305e-310e
90. Krueger J.K., and Rohrich R.J. Clearing the smoke: The scientific rationale for tobacco abstention with plastic surgery. Plast Reconstr Surg 108 (2001) 1063-1073
91. Imai E., Ueda M., Kanao K., et al. Surgical site infection risk factors identified by multivariate analysis for patient undergoing laparoscopic, open colon, and gastric surgery. Am J Infect Control 36 (2008) 727-731
92. Friedman N.D., Sexton D.J., Connelly S.M., and Kaye K.S. Risk factors for surgical site infection complicating laminectomy. Infect Control Hosp Epidemiol 28 (2007) 1060-1065
93. Gamboa-Bobadilla G.M., and Killingsworth C. Large-volume reduction mammaplasty: The effect of body mass index on postoperative complications. Ann Plast Surg 58 (2007) 246-249
94. Greco III J.A., Castaldo E.T., Nanney L.B., et al. Autologous breast reconstruction: The Vanderbilt experience (1998 to 2005) of independent predictors of displeasing outcomes. J Am Coll Surg 207 (2008) 49-56
95. Friedman N.D., Bull A.L., Russo P.L., et al. An alternative scoring system to predict risk for surgical site infection complicating coronary artery bypass graft surgery. Infect Control Hosp Epidemiol 28 (2007) 1162-1168
96. Watanabe A., Kohnoe S., Shimabukuro R., et al. Risk factors associated with surgical site infection in upper and lower gastrointestinal surgery. Surg Today 38 (2008) 404-412
97. Mangram A.J., Horan T.C., Pearson M.L., Silver L.C., and Jarvis W.R. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 20 (1999) 250-278
98. Centers for Medicare and Medicaid Services website. Hospital Quality Alliance 2004-2007 measure build out table. (Accessed 11/10/08, at http://www.cms.hhs.gov/HospitalQualityInits/downloads/HospitalHQA2004_2007200512.pdf)
99. Baran C.N., Sensoz O., and Ulusoy M.G. Prophylactic antibiotics in plastic and reconstructive surgery. Plast Reconstr Surg 103 (1999) 1561-1566
100. Kompatscher P., von Planta A., Spicher I., et al. Comparison of the incidence and predicted risk of early surgical site infections after breast reduction. Aesthetic Plast Surg 27 (2003) 308-314
101. Landes G., Harris P.G., Lemaine V., et al. Prevention of surgical site infection and appropriateness of antibiotic prescribing habits in plastic surgery. J Plast Reconstr Aesthet Surg 61 (2008) 1347-1356
102. Kalantar-Hormozi A.J., and Davami B. No need for preoperative antiseptics in elective outpatient plastic surgical operations: A prospective study. Plast Reconstr Surg 116 (2005) 529-531
103. Webster J., and Alghamdi A.A. Use of plastic adhesive drapes during surgery for preventing surgical site infection. Cochrane Database Syst Rev 4 (2007) CD006353.
104. Edwards P.S., Lipp A., and Holmes A. Preoperative skin antiseptics for preventing surgical wound infections after clean surgery. Cochrane Database Syst Rev 3 (2004) CD003949.
105. Webster J., and Osborne S. Preoperative bathing or showering with skin antiseptics to prevent surgical site infection. Cochrane Database Syst Rev 2 (2006) CD004985.
106. Webster J., and Osborne S. Preoperative bathing or showering with skin antiseptics to prevent surgical site infection. Cochrane Database Syst Rev 2 (2007) CD004985.
107. Kinirons B., Mimoz O., Lafendi L., Naas T., Meunier J., and Nordmann P. Chlorhexidine versus povidone iodine in preventing colonization of continuous epidural catheters in children: A randomized, controlled trial. Anesthesiology 94 (2001) 239-244
108. Ostrander R.V., Botte M.J., and Brage M.E. Efficacy of surgical preparation solutions in foot and ankle surgery. J Bone Joint Surg Am 87 (2005) 980-985
109. Digison M.B. A review of anti-septic agents for pre-operative skin preparation. Plast Surg Nurs 27 (2007) 185-189
110. Hibbard J.S. Analyses comparing the antimicrobial activity and safety of current antiseptic agents: A review. J Infus Nurs 28 (2005) 194-207
111. Corion L.U., Smeulders M.J., van Zuijlen P.P., and van der Horst C.M. Draining after breast reduction: A randomised, controlled inter-patient study. J Plast Reconstr Aesthet Surg (2008 Jun 16) (Epub ahead of print).
112. Collis N., McGuiness C.M., and Batchelor A.G. Drainage in breast reduction surgery: A prospective, randomised intra-patient trial. Br J Plast Surg 58 (2005) 286-289
113. Matarasso A., Wallach S.G., and Rankin M. Reevaluating the need for routine drainage in reduction mammaplasty. Plast Reconstr Surg 102 (1998) 1917-1921
114. Campbell Jr. D.A., Henderson W.G., Englesbe M.J., et al. Surgical site infection prevention: The importance of operative duration and blood transfusion-Results of the first American College of Surgeons-National Surgical Quality Improvement Program Best Practices Initiative. J Am Coll Surg 207 (2008) 810-820
115. Tang R., Chen H.H., Wang Y.L., et al. Risk factors for surgical site infection after elective resection of the colon and rectum: A single-center prosepective study of 2,809 consecutive patients. Ann Surg 234 (2001 Aug) 181-189
116. Kotsanas D., Scott C., Gillespie E.E., Korman T.M., and Stuart R.L. What's hanging around your neck? Pathogenic bacteria on identity badges and lanyards. Med J Aust 188 (2008) 5-8
117. Wong D., Nye K., and Hollis P. Microbial flora on doctors' white coats. BMJ 303 (1991) 1602-1604
118. Dixon M. Neck ties as vectors for nosocomial infection. Intensive Care Med 26 (2000) 250
119. French G., Rayner D., Branson M., and Walsh M. Contamination of doctors' and nurses' pens with nosocomial pathogens. Lancet 351 (1998) 213
120. Devine J., Cooke R.P., and Wright E.P. Is methicillin-resistant Staphylococcus aureus (MRSA) contamination of ward-based computer terminals a surrogate marker for nosocomial MRSA transmission and handwashing compliance?. J Hosp Infect 48 (2001) 72-75
121. Marinella M.A., Pierson C., and Chenoweth C. The stethoscope: A potential source of nosocomial infection?. Arch Intern Med 157 (1997) 786-790
122. Moolenaar R.L., Crutcher J.M., San Joaquin V.H., et al. A prolonged outbreak of Pseudomonas aeruginosa in a neonatal intensive care unit: Did staff fingernails play a role in disease transmission?. Infect Control Hosp Epidemiol 21 (2000) 80-85
123. Parry M.F., Grant B., Yukna M., et al. Candida osteomyelitis and diskitis after spinal surgery: An outbreak that implicates artificial nail use. Clin Infect Dis 32 (2001) 352-357
124. Baumgardner C.A., Maragos C.S., Walz J., and Larson E. Effects of nail polish on microbial growth of fingernails. Dispelling sacred cows. AORN J 58 (1993) 84-88
125. Pottinger J., Burns S., and Manske C. Bacterial carriage by artificial versus natural nails. Am J Infect Control 17 (1989) 340-344
126. Harbarth S., Fankhauser C., Schrenzel J., et al. Universal screening for methicillin-resistant Staphylococcus aureus at hospital admission and nosocomial infection in surgical patients. JAMA 299 (2008) 1149-1157
127. Siegel J.D., Rhinehart E., Jackson M., and Chiarello L-The Healthcare Infection Control Practices Advisory Committee. Management of multidrug-resistant organisms in healthcare settings, 2006. (Accessed 9/23/08, at http://www.cdc.gov/ncidod/dhqp/pdf/ar/mdroGuideline2006.pdf)
128. Weber S.G., Huang S.S., Oriola S., et al. Legislative mandates for use of active surveillance cultures to screen for methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: Position statement from the Joint SHEA and APIC Task Force. Am J Infect Control 35 (2007) 73-85
129. Diekema D.J., and Climo M. Preventing MRSA infections: Finding it is not enough. JAMA 299 (2008) 1190-1192
130. Rao N., Cannella B., Crossett L.S., Yates Jr. A.J., and McGough III R. A preoperative decolonization protocol for Staphylococcus aureus prevents orthopaedic infections. Clin Orthop Relat Res 466 (2008) 1343-1348
131. Davis K.A., Stewart J.J., Crouch H.K., Florez C.E., and Hospenthal D.R. Methicillin-resistant Staphylococcus aureus (MRSA) nares colonization at hospital admission and its effect on subsequent MRSA infection. Clin Infect Dis 39 (2004) 776-782
132. Ellis M.W., Hospenthal D.R., Dooley D.P., Gray P.J., and Murray C.K. Natural history of community-acquired methicillin-resistant Staphylococcus aureus colonization and infection in soldiers. Clin Infect Dis 39 (2004) 971-979
133. Abrahamian F.M., and Snyder E.W. Community-associated methicillin-resistant Staphylococcus aureus: Incidence, clinical presentation, and treatment decisions. Curr Infect Dis Rep 9 (2007) 391-397
134. Harbarth S., Dharan S., Liassine N., Herrault P., Auckenthaler R., and Pittet D. Randomized, placebo-controlled, double-blind trial to evaluate the efficacy of mupirocin for eradicating carriage of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 43 (1999) 1412-1416
135. Dupeyron C., Campillo B., Bordes M., Faubert E., Richardet J.P., and Mangeney N. A clinical trial of mupirocin in the eradication of methicillin-resistant Staphylococcus aureus nasal carriage in a digestive disease unit. J Hosp Infect 52 (2002) 281-287
136. Ellis M.W., Griffith M.E., Dooley D.P., et al. Targeted intranasal mupirocin to prevent colonization and infection by community-associated methicillin-resistant Staphylococcus aureus strains in soldiers: A cluster randomized, controlled trial. Antimicrob Agents Chemother 51 (2007) 3591-3598
137. Simor A.E., Phillips E., McGeer A., et al. Randomized controlled trial of chlorhexidine gluconate for washing, intranasal mupirocin, and rifampin and doxycycline versus no treatment for the eradication of methicillin-resistant Staphylococcus aureus colonization. Clin Infect Dis 44 (2007) 178-185
138. Wendt C., Schinke S., Wurttemberger M., Oberdorfer K., Bock-Hensley O., and von Baum H. Value of whole-body washing with chlorhexidine for the eradication of methicillin-resistant Staphylococcus aureus: A randomized, placebo-controlled, double-blind clinical trial. Infect Control Hosp Epidemiol 28 (2007) 1036-1043
139. Loeb M., Main C., Walker-Dilks C., and Eady A. Antimicrobial drugs for treating methicillin-resistant Staphylococcus aureus colonization. Cochrane Database Syst Rev 4 (2003) CD003340.
140. Perl T.M., Cullen J.J., Wenzel R.P., et al. Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. N Engl J Med 346 (2002) 1871-1877
141. Veiga D.F., Damasceno C.A., Veiga Filho J., et al. Influence of povidone-iodine preoperative showers on skin colonization in elective plastic surgery procedures. Plast Reconstr Surg 121 (2008) 115-118
142. Stevens D.L., Bisno A.L., Chambers H.F., et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 41 (2005) 1373-1406
143. Strenge K.B., Mangan D.B., and Idusuyi O.B. Postoperative toxic shock syndrome after excision of a ganglion cyst from the ankle. J Foot Ankle Surg 45 (2006) 275-277
144. Raab M.G., O'Brien M., Hayes J.M., and Graham D.R. Postoperative toxic shock syndrome. Am J Orthop 24 (1995) 130-136
145. Bartlett P., Reingold A.L., Graham D.R., et al. Toxic shock syndrome associated with surgical wound infections. JAMA 247 (1982) 1448-1450
146. LoVerme W.E., Drapkin M.S., Courtiss E.H., and Wilson R.M. Toxic shock syndrome after chemical face peel. Plast Reconstr Surg 80 (1987) 115-118
147. Tobin G., Shaw R.C., and Goodpasture H.C. Toxic shock syndrome following breast and nasal surgery. Plast Reconstr Surg 80 (1987) 111-114
148. Umeda T., Ohara H., Hayashi O., Ueki M., and Hata Y. Toxic shock syndrome after suction lipectomy. Plast Reconstr Surg 106 (2000) 204-207
149. American Academy of Pediatrics. Red book: 2006 report of the Committee on Infectious Diseases. 27th ed. (2006), American Academy of Pediatrics, Elk Grove Village, IL
150. Wharton M., Chorba T.L., Vogt R.L., Morse D.L., and Buehler J.W. Case definitions for public health surveillance. MMWR Recomm Rep 39 (1990) 1-43
151. Bobrow B.J., Pollack Jr. C.V., Gamble S., and Seligson R.A. Incision and drainage of cutaneous abscesses is not associated with bacteremia in afebrile adults. Ann Emerg Med 29 (1997) 404-408
152. Jernigan J.A., Titus M.G., Groschel D.H., Getchell-White S., and Farr B.M. Effectiveness of contact isolation during a hospital outbreak of methicillin-resistant Staphylococcus aureus. Am J Epidemiol 143 (1996) 496-504
153. Safdar N., Marx J., Meyer N.A., and Maki D.G. Effectiveness of preemptive barrier precautions in controlling nosocomial colonization and infection by methicillin-resistant Staphylococcus aureus in a burn unit. Am J Infect Control 34 (2006) 476-483
154. Siegel J.D., Rhinehart E., Jackson M., and Chiarello L-The Healthcare Infection Control Practices Advisory Committee. 2007 guideline for isolation precautions: Preventing transmission of infectious agents in healthcare settings. (Accessed 12/1/2008, at http://www.cdc.gov/ncidod/dhqp/pdf/isolation2007.pdf)
155. Stelfox H.T., Bates D.W., and Redelmeier D.A. Safety of patients isolated for infection control. JAMA 290 (2003) 1899-1905
156. Evans H.L., Shaffer M.M., Hughes M.G., et al. Contact isolation in surgical patients: A barrier to care?. Surgery 134 (2003) 180-188
157. Saint S., Higgins L.A., Nallamothu B.K., and Chenoweth C. Do physicians examine patients in contact isolation less frequently? A brief report. Am J Infect Control 31 (2003) 354-356
158. Blot S.I., Vandewoude K.H., Hoste E.A., and Colardyn F.A. Outcome and attributable mortality in critically ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Arch Intern Med 162 (2002) 2229-2235
159. Shurland S., Zhan M., Bradham D.D., and Roghmann M.C. Comparison of mortality risk associated with bacteremia due to methicillin-resistant and methicillin-susceptible Staphylococcus aureus. Infect Control Hosp Epidemiol 28 (2007) 273-279
160. Tacconelli E., Pop-Vicas A.E., and D'Agata E.M. Increased mortality among elderly patients with meticillin-resistant Staphylococcus aureus bacteraemia. J Hosp Infect 64 (2006) 251-256
161. Wang F.D., Chen Y.Y., Chen T.L., and Liu C.Y. Risk factors and mortality in patients with nosocomial Staphylococcus aureus bacteremia. Am J Infect Control 36 (2008) 118-122
162. Harbarth S., Rutschmann O., Sudre P., and Pittet D. Impact of methicillin resistance on the outcome of patients with bacteremia caused by Staphylococcus aureus. Arch Intern Med 158 (1998) 182-189
163. Wang J.L., Chen S.Y., Wang J.T., et al. Comparison of both clinical features and mortality risk associated with bacteremia due to community-acquired methicillin-resistant Staphylococcus aureus and methicillin-susceptible S aureus. Clin Infect Dis 46 (2008) 799-806
164. Haessler S., Mackenzie T., and Kirkland K.B. Long-term outcomes following infection with meticillin-resistant or meticillin-susceptible Staphylococcus aureus. J Hosp Infect 69 (2008) 39-45
165. Reed S.D., Friedman J.Y., Engemann J.J., et al. Costs and outcomes among hemodialysis-dependent patients with methicillin-resistant or methicillin-susceptible Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol 26 (2005) 175-183
166. Cosgrove S.E., Qi Y., Kaye K.S., Harbarth S., Karchmer A.W., and Carmeli Y. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: Mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol 26 (2005) 166-174
167. Laying down the law on healthcare-associated infections. Lancet Infect Dis 8 (2008) 583
168. Edmond M.B., and Bearman G.M. Mandatory public reporting in the USA: An example to follow?. J Hosp Infect 65 Suppl 2 (2007) 182-188
169. McCaughey B. Hospital infections: Preventable and unacceptable. Wall Street Journal (August 14, 2008) A11
170. Naimi T.S., LeDell K.H., Como-Sabetti K., et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 290 (2003) 2976-2984
171. Okuma K., Iwakawa K., Turnidge J.D., et al. Dissemination of new methicillin-resistant Staphylococcus aureus clones in the community. J Clin Microbiol 40 (2002) 4289-4294